Department of Obstetrics and Reproductive Medicine, Hôpital Tenon, 4 rue de la Chine, 75020 Paris, France; Clinical Research Group (GRC) Paris 6: Centre Expert Endométriose (C3E), Sorbonne University (GRC6 C3E SU), France.
Ziwig, 19 rue Reboud, Lyon, France.
Eur J Obstet Gynecol Reprod Biol. 2023 Dec;291:88-95. doi: 10.1016/j.ejogrb.2023.10.015. Epub 2023 Oct 13.
In contrast to miRNA expression, little attention has been given to piwiRNA (piRNA) expression among endometriosis patients. The aim of the present study was to explore the human piRNAome and to investigate a potential piRNA saliva-based diagnostic signature for endometriosis.
Data from the prospective "ENDOmiRNA" study (ClinicalTrials.gov Identifier: NCT04728152) were used. Saliva samples from 200 patients were analyzed in order to evaluate human piRNA expression using the piRNA bank. Next Generation Sequencing (NGS), barcoding of unique molecular identifiers and both Artificial Intelligence (AI) and machine learning (ML) were used. For each piRNA, sensitivity, specificity, and ROC AUC values were calculated for the diagnosis of endometriosis.
201 piRNAs were identified, none had an AUC ≥ 0.70, and only three piRNAs (piR-004153, piR001918, piR-020401) had an AUC between ≥ 0.6 and < 0.70. Seven were differentially expressed: piR-004153, piR-001918, piR-020401, piR-012864, piR-017716, piR-020326 and piR-016904. The respective correlation and accuracy to diagnose endometriosis according to the F1-score, sensitivity, specificity, and AUC ranged from 0 to 0.862 %, 0-0.961 %, 0.085-1, and 0.425-0.618. A correlation was observed between the patients' age (≥35 years) and piR-004153 (p = 0.002) and piR-017716 (p = 0.030). Among the 201 piRNAs, four were differentially expressed in patients with and without hormonal treatment: piR-004153 (p = 0.015), piR-020401 (p = 0.001), piR-012864 (p = 0.036) and piR-017716 (p = 0.009).
Our results support the link between piRNAs and endometriosis physiopathology and establish its utility as a potential diagnostic biomarker using saliva samples. Per se, piRNA expression should be analyzed along with the clinical status of a patient.
与 miRNA 表达相比,子宫内膜异位症患者的 piwiRNA(piRNA)表达尚未得到太多关注。本研究旨在探索人类 piRNA 组,并研究一种基于唾液的子宫内膜异位症潜在 piRNA 诊断特征。
使用前瞻性“ENDOmiRNA”研究(ClinicalTrials.gov 标识符:NCT04728152)的数据。分析了 200 名患者的唾液样本,以使用 piRNA 库评估人类 piRNA 表达。使用下一代测序(NGS)、独特分子标识符的条形码以及人工智能(AI)和机器学习(ML)。对于每个 piRNA,计算了用于诊断子宫内膜异位症的敏感性、特异性和 ROC AUC 值。
鉴定出 201 个 piRNA,没有一个 AUC≥0.70,只有三个 piRNA(piR-004153、piR001918、piR-020401)的 AUC 在≥0.6 和<0.70 之间。七个表现出差异表达:piR-004153、piR-001918、piR-020401、piR-012864、piR-017716、piR-020326 和 piR-016904。根据 F1 评分、敏感性、特异性和 AUC,各自与诊断子宫内膜异位症的相关性和准确性的范围为 0 到 0.862%、0 到 0.961%、0.085 到 1 和 0.425 到 0.618。观察到患者年龄(≥35 岁)与 piR-004153(p=0.002)和 piR-017716(p=0.030)之间存在相关性。在 201 个 piRNA 中,有四个在接受和未接受激素治疗的患者中表现出差异表达:piR-004153(p=0.015)、piR-020401(p=0.001)、piR-012864(p=0.036)和 piR-017716(p=0.009)。
我们的结果支持 piRNA 与子宫内膜异位症病理生理学之间的联系,并确立了其使用唾液样本作为潜在诊断生物标志物的效用。单独地,应该分析 piRNA 表达与患者的临床状况一起进行分析。